SIRT1 Regulates Hepatocyte Programmed Cell Death via GSDME - IL18 Axis in Human and Mouse Liver Transplantation.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
27 Jun 2023
Historique:
pubmed: 18 7 2023
medline: 18 7 2023
entrez: 18 7 2023
Statut: epublish

Résumé

Sirtuin 1 (SIRT1) is a histone/protein deacetylase involved in cellular senescence, inflammation, and stress resistance. We previously reported that myeloid SIRT1 signaling regulates the inflamed liver's canonical pyroptosis cell death pathway. However, whether/how hepatocyte SIRT1 is engaged in programmed cell death in the cold-stressed liver remains uncertain. Here, we undertook translational studies in human and mouse orthotopic liver transplantation (OLT) to interrogate the significance of hepatocyte-specific SIRT1 signaling in cold-stored donor livers and liver grafts after reperfusion. In the clinical arm of sixty human OLT patients, hepatic SIRT1 levels in cold-preserved donor livers correlated with anti-apoptotic Bcl-2 expression. After reperfusion, improved OLT function was accompanied by hepatic SIRT1 levels negatively associated with cleaved caspase-3 expression. In the experimental arm, we compared FLOX-control with hepatocyte-specific SIRT1-KO livers after orthotopic transplantation into WT mouse recipients, parallel with primary murine hepatocyte cultures subjected to cold activation with/without knockdown of SIRT1, GSDME, and IL18Rβ signaling. Hepatocyte SIRT1 deficiency upregulated apoptosis and GSDME-mediated programmed cell death, which in turn deteriorated the hepatocellular function and shortened OLT survival. Augmented GSDME processing, accompanied by increased secretion of IL18 by stressed hepatocytes, was prominent in SIRT1-deficient, cold-stored livers. Hepatocyte SIRT1 signaling regulated anti-apoptotic Bcl-2/XIAP proteins, suppressed cold stress-triggered apoptosis, and mitigated GSDME licensing to release IL18. Notably, while crosslinking IL18R depressed SIRT1 and Bcl-2/XIAP signaling

Identifiants

pubmed: 37461687
doi: 10.21203/rs.3.rs-2986981/v1
pmc: PMC10350112
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI120944
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI155856
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK062357
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK107533
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

COMPETING INTERESTS The authors declare that they have no conflict of interest.

Auteurs

Kentaro Kadono (K)

David Geffen School of Medicine, University of California-Los Angeles.

Hidenobu Kojima (H)

David Geffen School of Medicine, University of California-Los Angeles.

Siyuan Yao (S)

David Geffen School of Medicine, University of California-Los Angeles.

Shoichi Kageyama (S)

David Geffen School of Medicine, University of California-Los Angeles.

Hirofumi Hirao (H)

David Geffen School of Medicine, University of California-Los Angeles.

Takahiro Ito (T)

David Geffen School of Medicine, University of California-Los Angeles.

Kenneth Dery (K)

David Geffen School of Medicine, University of California-Los Angeles.

Douglas Farmer (D)

The Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles.

Fady Kaldas (F)

The Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles.

Xiaoling Li (X)

Signal Transduction Laboratory, National Institute of Environmental Health Sciences.

Jerzy Kupiec-Weglinski (J)

David Geffen School of Medicine, University of California-Los Angeles.

Classifications MeSH